Synthesis and α-glucosidase inhibitory activity evaluation of N-substituted aminomethyl-β-d-glucopyranosides

Abstract

A series of N-substituted 1-aminomethyl-β-d-glucopyranoside derivatives was prepared. These novel synthetic compounds were assessed in vitro for inhibitory activity against yeast α-glucosidase and both rat intestinal α-glucosidases maltase and sucrase. Most of the compounds displayed α-glucosidase inhibitory activity, with IC50 values covering the wide range from 2.3μM to 2.0mM. Compounds 19a (IC50=2.3μM) and 19b (IC50=5.6μM) were identified as the most potent inhibitors for yeast α-glucosidase, while compounds 16 (IC50=7.7 and 15.6μM) and 19e (IC50=5.1 and 10.4μM) were the strongest inhibitors of rat intestinal maltase and sucrase. Analysis of the kinetics of enzyme inhibition indicated that 19e inhibited maltase and sucrase in a competitive manner. The results suggest that the aminomethyl-β-d-glucopyranoside moiety can mimic the substrates of α-glucosidase in the enzyme catalytic site, leading to competitive enzyme inhibition. Moreover, the nature of the N-substituent has considerable influence on inhibitory potency.

N-Arylmethylaminoquercitols, a new series of effective antidiabetic agents having α-glucosidase inhibition and antioxidant activity

“…In addition, the replacement of hydroxyl group in (+)-proto-quercitol by amino residue is expected to enhance a-glucosidase inhibition of the synthesized bioconjugates, possibly by tight binding with active site of the enzyme. 3 This postulation was also supported by previous reports of N-arylalkylaminocyclitols (Scheme 1) as potent glycosidase inhibitors. 4 Although a variety of aminocyclitols have been synthesized, 5 other related bioactivities have rarely been reported.…”

A new dinuclear copper (II) complex of 2,5–Furandicarboxyclic acid with 4(5)‐Methylimidazole as a high potential α‐glucosidase inhibitor: Synthesis, Crystal structure, Cytotoxicity study, and TD/DFT calculations

“…α‐Glucosidase inhibitors (AGI) delay carbohydrate digestion and prolong the overall carbohydrate digestion period, slowing glucose uptake and thus blunting post‐prandial plasma glucose increase. A variety of AGIs including acarbose, voglibose and miglitol molecules have been effectively used clinically to treat type 2 diabetes mellitus . However, there are only a few AGIs commercially available and they do not meet their needs due to the side effects.…”

Recent Advances in Synthetic α‐Glucosidase Inhibitors

“…On the basis of the commons tructures of acarbose, voglibose and miglitol, Bian et al [8] have designed as eries of monosaccharide derivatives with general structure A ( Figure 3). Amongt hese derivatives, compound 1 has been identified as the most potent inhibitor for yeast a-glucosidase (IC 50 = 2.3 mm)u sing acarbose (IC 50 = 235.1 mm)a sacontrol.…”